Yet, the prognostic significance of pCR after neoadjuvant chemotherapy remains somewhat controversial. 3 The neoadjuvant therapy model provides a potential efficient trial design to explore the efficacy of novel therapies utilizing pathological complete response (pCR) as a surrogate marker for disease free-survival and overall survival. 2 Because the primary tumor remains intact during therapy, the neoadjuvant treatment strategy allows for monitoring of treatment response and discontinuing of therapy in the event of disease progression.įrom a research perspective, the neoadjuvant setting has become recognized as a human in vivo system to evaluate predictive biomarkers, surrogate endpoints, and the efficacy of therapies including novel agents. 1, 2 NAT for breast cancer is an established therapeutic option for selected high-risk, locally advanced or unresectable breast cancers, or to improve eligibility for breast conserving surgery (BCS). ![]() Studies have demonstrated no difference in survival between adjuvant or neoadjuvant setting. Neoadjuvant chemotherapy (NAT) is increasingly being utilized as the frontline therapy for the management of high-risk localized breast cancer.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |